Related Experiment Video
Updated: Jul 7, 2026
07:36
Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
Published on: December 23, 2022
Quantitative Analysis of Placebo Response Models to Optimize Clinical Trials in Premenstrual Disorders: A Model-Based
Biopsychosocial Science and Medicine
|July 6, 2026
Summary
This study analyzed placebo responses in premenstrual disorder clinical trials, establishing models for key indicators. The total symptom score is recommended as the primary outcome for future trial design.
Area of Science:
- Clinical trials methodology
- Psychopharmacology
- Women's health research
Background:
- Premenstrual disorders (PMD) significantly impact women's quality of life.
- Clinical trials for PMD treatments face challenges due to placebo response variability.
- Standardized evaluation indicators are crucial for reliable PMD clinical trial outcomes.
Purpose of the Study:
- To quantitatively analyze evaluation indicators in premenstrual disorder clinical trials.
- To establish and analyze placebo response models and their influencing factors.
- To provide a data-driven basis for optimizing future clinical trial designs in PMD.
Main Methods:
- Systematic literature search of randomized controlled trials (RCTs) for premenstrual disorders across major databases.
- Time-course modeling and analysis of placebo responses for common evaluation indicators.
- Simulation of placebo responses under various conditions to inform external control and sample size estimation.
Main Results:
- Analysis of 47 RCTs involving 5406 patients identified five key indicators: total symptom score, depression, anxiety, irritability, and physical symptom scores.
- Maximum placebo response ranged from 20.9% to 38.4%, with plateau effects observed within 2-3 months.
- Total symptom score recommended as primary outcome due to minimal placebo effect, rapid onset, and low variability; natural S-equol showed no significant difference from placebo.
Conclusions:
- Established placebo response models for common indicators in premenstrual disorder clinical trials.
- The models provide a crucial foundation for optimizing the design and decision-making processes of subsequent clinical trials.
- Accurate effect sizes for sample size estimation were achieved using the developed placebo response models.
Related Concept Videos
01:09Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
01:29Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
01:54The Placebo Effect
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:27Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...